Opdivo (nivolumab) First PD-1 Inhibitor to Demonstrate Superior Overall Survival Versus Standard of Care (docetaxel) in Previously-Treated Non-Squamous Non-Small Cell Lung Cancer in Pivotal Phase III Trial

… ) in Previously-Treated Non-Squamous Non-Small Cell Lung Cancer in Pivotal Phase III Trial … survival expectations for patients with lung cancer,” said Michael Giordano, senior vice … previously-treated advanced squamous non-small cell lung cancer and formed the basis of …